Cyteir Therapeutics, Inc.
NASDAQ:CYT
3.02 (USD) • At close March 15, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.1 | 0.1 | 0.308 | 0.326 | 0.2 | 0.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.1 | -0.1 | -0.308 | -0.326 | -0.2 | -0.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 2.676 | 5.403 | 9.312 | 7.47 | 8.272 | 8.794 | 10.088 | 8.255 | 8.205 | 8.886 | 5.613 | 3.917 | 4.214 | 3.633 | 5.001 |
| General & Administrative Expenses
| 2.495 | 4.204 | 4.11 | 2.583 | 3.487 | 3.433 | 4.043 | 3.607 | 3.547 | 2.422 | 1.724 | 1.463 | 0.831 | 0.875 | 1.009 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 2.495 | 4.204 | 4.11 | 2.583 | 3.487 | 3.433 | 4.043 | 3.607 | 3.547 | 2.422 | 1.724 | 1.463 | 0.831 | 0.875 | 1.009 |
| Other Expenses
| 0 | 0 | 0 | 1.26 | 0.714 | 0.106 | 0.029 | 0.047 | 0.048 | 0.013 | 0.025 | 0.02 | 0.009 | 0.01 | 0.081 |
| Operating Expenses
| 5.171 | 9.607 | 13.422 | 10.053 | 11.759 | 12.227 | 14.131 | 11.862 | 11.752 | 11.308 | 7.337 | 5.38 | 5.045 | 4.508 | 6.01 |
| Operating Income
| -5.171 | -9.607 | -13.422 | -10.053 | -11.759 | -12.227 | -14.131 | -11.862 | -11.752 | -11.308 | -7.337 | -5.38 | -5.045 | -4.508 | -6.01 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 1.639 | 1.203 | 0.936 | 1.26 | 0.714 | 0.106 | 0.029 | 0.047 | 0.048 | 0.013 | 0.025 | 0.02 | 0.009 | 0.01 | 0.081 |
| Income Before Tax
| -3.532 | -8.404 | -12.486 | -8.793 | -11.045 | -12.121 | -14.102 | -11.815 | -11.704 | -11.295 | -7.312 | -5.36 | -5.036 | -4.498 | -5.929 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -0.936 | -1.395 | -0.714 | -0.106 | -0.029 | -0.14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income
| -3.532 | -8.404 | -11.55 | -7.398 | -10.331 | -12.015 | -14.073 | -11.815 | -11.704 | -11.295 | -7.312 | -5.36 | -5.036 | -4.498 | -5.929 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.098 | -0.24 | -0.32 | -0.21 | -0.29 | -0.34 | -0.4 | -0.34 | -0.33 | -4.83 | -0.21 | -0.22 | -0.21 | -0.19 | -0.25 |
| EPS Diluted
| -0.098 | -0.24 | -0.32 | -0.21 | -0.29 | -0.34 | -0.4 | -0.34 | -0.33 | -4.83 | -0.21 | -0.22 | -0.21 | -0.19 | -0.25 |
| EBITDA
| -5.061 | -9.499 | -12.815 | -10.053 | -11.589 | -12.058 | -13.972 | -11.862 | -11.627 | -11.197 | -7.234 | -5.285 | -4.938 | -4.426 | -5.943 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |